Overview

Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis

Status:
Active, not recruiting
Trial end date:
2022-10-05
Target enrollment:
Participant gender:
Summary
This study will investigate the safety and efficacy of VAY736 administered subcutaneously (s.c.) every 4 weeks for 48 weeks. Approximately, 84 subjects will be randomized in a 1:1 ratio on top of local standard of care (SOC), to receive VAY736 or placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals